Stockreport

Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasi...

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF FDA requests study amendment to allow inclusion of children ages 2 to 11 years in the DERMIS-1 and DERMIS-2 trialsStrong safety profile supported population expansion in [Read more]